Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Horizon Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
January 30, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 15 (c) Announcement – Horizon Therapeutics plc
January 27, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 17 (b) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 17 (a) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
January 18, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 2.12 Announcement – Horizon Therapeutics plc
January 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 03, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
December 20, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Form 8.1 Opening Position Disclosure (Horizon Therapeutics plc)
December 13, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
December 12, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
November 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
November 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
November 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
November 10, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
November 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
November 05, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
November 02, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named to the Seramount Inclusion Index
November 01, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
October 26, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
October 22, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
October 13, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
October 12, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
October 06, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
October 06, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
October 02, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
September 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.